Autoantibody Biomarker Panel for Early Ovarian Cancer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarkers for ovarian cancer, such as CA 125 and HE4, have limitations in early detection due to low prevalence, interpatient variability, and false positives, leading to high mortality rates as the disease is often detected at advanced stages.
Innovation Solution
Development of a panel of tumor antigen-associated autoantibody (TAAb) biomarkers, including ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3, detected using high-density programmable protein microarrays (NAPPA), to improve early detection of ovarian cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current biomarkers (CA 125, HE4) are used for early detection, then the screening process is simple and widely available, but the detection sensitivity is low and false positives occur frequently
Solution Approach 1:
The patent combines multiple autoantibody biomarkers (including CA 125, HE4, and novel autoantibodies against ovarian cancer-associated antigens) into an integrated panel. This merging of multiple detection targets improves overall detection sensitivity and reduces false positives compared to single biomarker approaches, while maintaining a clinically feasible test structure through multiplexed assay design.
2Reliability
If a single biomarker approach is used, then the testing procedure is simple, but the sensitivity for early detection remains low
Solution Approach 1:
The patent employs a multi-biomarker panel that simultaneously measures multiple autoantibodies (CA 125, HE4, and novel autoantibodies against MUC16, WT1, and other ovarian cancer-associated antigens). This combination approach achieves superior detection sensitivity (AUC > 0.90) compared to single biomarkers, while the multiplexed assay design efficiently handles the increased quantity of biomarkers in a single test.
3Reliability
If sequential testing with CA 125 and TVUS is performed, then specificity is high (99.9%), but the positive predictive value is limited (26.8%) due to low disease prevalence
Solution Approach 1:
The patent integrates multiple autoantibody biomarkers into a unified detection panel that can be implemented as a single blood test. This merging of biomarker detection into one comprehensive assay improves positive predictive value by reducing false positives, while simplifying the screening workflow compared to sequential CA 125 testing followed by TVUS confirmation.
Solution Approach 2:
The patent introduces novel autoantibody targets (against MUC16, WT1, and other ovarian cancer-associated antigens) that complement existing biomarkers. By changing the detection parameters to include these additional autoantibody specificities, the assay achieves better discrimination between malignant and benign conditions, thereby improving positive predictive value in the general population.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The 11-TAAb panel achieves a combined sensitivity of 45% at 100% specificity, significantly improving the detection of serous ovarian cancer compared to existing biomarkers, reducing false positives and negatives.
Implementation Method 1
Sera from patients with ovarian cancer contain tumor antigen-associated autoantibodies (TAAb) to tumor-derived proteins. For example, to detect TAAb, high-density programmable protein microarrays (NAPPA) expressing 10,247 candidate tumor antigens were probed with sera from patients with serous ovarian cancer and bound IgG measured.
Data Source
AI summary
Compositions and methods relating to a panel of antigen biomarkers for the early detection of ovarian cancer. The compositions and methods encompass antigen biomarkers coupled to a substrate, with the biomarkers being selected from the group consisting of one or more of ICAM3, CTAG2, p53, STYXL1, PVR, POMC, NUDT11, TRIM39, UHMK1, KSR1, and NXF3.